<DOC>
	<DOCNO>NCT00077584</DOCNO>
	<brief_summary>In early clinical trial , RAPIDS-1 , conduct scleroderma patient without digital ulcer baseline , bosentan significantly reduce number new digital ulcer versus placebo . The purpose present trial ( RAPIDS-2 ) evaluate prevention healing effect bosentan versus placebo digital ulcer 24-week treatment period .</brief_summary>
	<brief_title>Efficacy Safety Oral Bosentan Healing/Prevention Digital ( Finger ) Ulcers Patients With Scleroderma</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Skin Ulcer</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Main Systemic Sclerosis ( SSc ) , diffuse limited . SSc patient least one digital ulcer baseline qualify cardinal ulcer . Main Digital ulcer due condition SSc . Severe pulmonary arterial hypertension ( PAH ) ( Who class III IV ) . Malabsorption severe organ failure ( e.g. , lung , kidney , liver ) lifethreatening condition . Treatment parenteral prostanoids ( prostaglandin E , epoprostenol , prostacyclin analog ) past 3 month prior randomization . Treatment inhale oral prostanoids one month prior randomization . Previous treatment bosentan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Scleroderma</keyword>
	<keyword>Finger Ulcers</keyword>
	<keyword>Digital Ulcers</keyword>
	<keyword>Systemic Sclerosis</keyword>
</DOC>